Dan Theodorescu, MD, PhD
Theodorescu has emerged as a leading translational cancer researcher focusing on bladder cancer. His pioneering application of computational biology led to the discovery of genes that regulate metastasis (RhoGDI2) in bladder and other cancers, and provided novel biomarkers and concepts for precision therapeutic approaches such as the COXEN principle, that are currently being tested in national (SWOG) clinical trials. He has also conceptualized the approach and then led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in several human cancer types. Trained as a urologist and then as a urologic oncologistat the University of Toronto and MSKCC, his experience as a urologist, in biotech, academic administration and in interactions with elected officials has provided him with insights on how relationships between medical staff, academic, commercial and governmental entities can be crafted to improve local, regional and national health care.
As Director of the University of Colorado Comprehensive Cancer Center, he has led the center to successfully be elected into the National Comprehensive Cancer (NCCN) and Oncology Research Information Exchange (ORIEN) Networks and rise in US News and World Report rankings. His laboratory is currently funded by the NIH-NCI and he is an elected member of the American Society for Clinical Investigation (ASCI), the American Association of Genitourinary Surgeons (AAGUS), the American Surgical Association (ASA) and the National Academy of Medicine (NAM)
For more information on Dr. Theodorescu’s research and practice, please visit the Colorado Cancer Center website.